Antimalarials

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Definition
This section has been translated automatically.

Effective against plasmodia, but also widely (indispensably) used in the treatment of inflammatory diseases.

Definition
This section has been translated automatically.

A group of drugs effective against plasmodia, which has also found broad (indispensable) use in the treatment of inflammatory diseases.

Note(s)
This section has been translated automatically.

General questions about treatment with antimalarials

When can an effect be expected?

  • Most patients notice an improvement only after 3 to 4 months. In a few patients it can also take up to ½ years before an effect is felt. In rheumatism patients, in patients with lupus erythematosus morning stiffness and tiredness decrease.

How is the treatment with anti-malarial drugs carried out?

  • Antimalarial drugs are only available in tablet form. In general, the dose depends on your body weight, but also on the nature of your disease. Your doctor will explain this to you in more detail.

Can antimalarials be combined with other medicines?

  • Yes, the anti-malarials can be combined with other medicines very well. Especially at the beginning of the treatment, when their effect has not yet been fully achieved, the antimalarial therapy can be supplemented with non-steroidal anti-rheumatic drugs or with preparations containing cortisone in the case of rheumatic diseases. With these combinations the initial phase can be bridged well.

How long must a treatment be carried out?

  • Treatment with antimalarial drugs is a long-term therapy, lasting many months, sometimes years. Important: It will only be successful if you take the medication regularly.

Does it happen that the treatment with anti-malarial drugs is not effective or not sufficient?

  • This question can certainly only be answered after 4-6 months. If the treatment effect is not sufficient after ½ year, your doctor will either discontinue the treatment or supplement it with another drug. How this is done, however, depends very much on the nature of your illness.

What side effects can occur?

  • Basically it can be said that there is no effective medication without any side effects. However, most of the side effects of antimalarial therapy are harmless. Nausea, vomiting, sometimes headaches, tiredness and dizziness can occur in some patients. These symptoms are most noticeable in the first weeks of treatment.

Do antimalarial drugs affect the eyes?

  • In the first few days, vision problems such as blurred vision, sensitivity to light or changes in colour vision can rarely occur. These symptoms disappear after a short time. They are not dangerous. Possibly they hinder driving a car.

Are there any dangerous side effects on the eyes?

  • Before starting and during the treatment with anti-malaria drugs you must have regular check-ups by an ophthalmologist. During the treatment, deposits in the cornea, very rarely retinal changes may occur. They depend on the dose. These changes are easy to detect. The dose is then adjusted. In very rare cases, you may have to stop taking the medication. The cause of the previously feared "irreversible retinopathy" (shooting target maculopathy) was due to an overdose.

Pregnancy and antimalarials.

  • Antimalarials are used without known risks in pregnancy and lactation. After consultation with your doctor, the therapy can therefore be continued during pregnancy and breastfeeding if necessary.

Kidney diseases and antimalarials:

  • In advanced kidney disease (renal insufficiency -GFR < 30 ml/min) the daily dose should be reduced accordingly. In dialysis patients the dose is reduced to 15% of the normal dose.

Should smoking be stopped during the treatment?

  • Smoking and antimalarials: In our opinion and in the opinion of many doctors, smoking reduces the effect of the antimalarials. For all patients with e.g. SLE, nicotine withdrawal should be observed.

Literature
This section has been translated automatically.

  1. Ochsendorf FR (2010) Use of antimalarials in dermatology. JJDG8: 929-845

Tables
This section has been translated automatically.

Substances and spectra of action of antimalarials

Substance

Spectrum of action

Amodiaquines

schizontoid, gametozide against Pl. vivax, Pl. ovale and Pl. malariae, no effect on the resting forms in the liver

Arthemeter/Artesunat/Arteether

Effective against Pl. falciparum (also against chloroquine resistance), effective against sexually mature forms (gametocytes); not for prophylaxis

Atovaquon

Only for prophylaxis, not suitable for therapy; rapid development of resistance when used as a mono-preparation, therefore only used in combination preparations; effective against liver schizophrenia and blood forms

quinine

schizontoid, gametozide against Pl. vivax, Pl. ovale and Pl. malariae, no effect on the resting forms in the liver

Chloroquine, hydroxychloroquine

schizontoid, gametozide against Pl. vivax, Pl. ovale and Pl. malariae, no effect on the resting forms in the liver

Halofrantin

Effective against all stages of all plasmodia

Lumefantrine

Effective against Pl. falciparum (also against chloroquine resistance), not for prophylaxis

Mefloquine

Effective against all asexual stages of Pl. falciparum and Pl. vivax

Primaquine

Gametocide against Pl. falciparum, eliminates extraerythrocytic forms of Pl. vivax and Pl. ovale in the liver

Proguanil

Only for prophylaxis, not suitable for therapy; rapid development of resistance when used as a mono-preparation, therefore only used in combination preparations; effective against liver schizophrenia and blood forms

Pyrimethamine

Inhibition of the proliferation of all plasmodia; only for use in combination therapies, not suitable for prophylaxis

Literature
This section has been translated automatically.

  1. Ochsendorf FR (2010) Use of antimalarials in dermatology. JDDG 8: 829-845
  2. Mittal L et al (2018) Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study. J Am Acad Dermatol 78:100-106.

Authors

Last updated on: 29.10.2020